Merck stock performance snapshot and recent context

Merck (MRK) trades around $113.45, with the stock roughly flat over the past week and down about 6% over the past month and 5% over the past 3 months. This sets the backdrop for a closer look at its fundamentals.

While the 30 day share price return declined 5.6% and the 90 day share price return declined 4.9%, the year to date share price return of 6.6% and 1 year total shareholder return of 60.0% indicate earlier momentum that has cooled recently as investors reassess growth prospects and risks.

If you are looking beyond large pharmaceutical stocks, this could be a useful moment to broaden your watchlist with 33 healthcare AI stocks

So with Merck trading near $113.45 after strong 1 year and 5 year total returns, yet reportedly sitting at a 50% intrinsic discount, is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 1% Overvalued

According to the most followed narrative, Merck's fair value sits around $112.55, almost in line with the last close at $113.45. This keeps expectations finely balanced.

Merck & Co. presents a compelling long-term investment case, underpinned by its innovative capacity and strong market position. The current valuation, considering both quantitative metrics and qualitative factors, suggests an attractive entry point for investors willing to weather near-term volatility. However, the looming Keytruda patent expiration necessitates close monitoring of pipeline developments and competitive dynamics.

Curious what keeps that fair value so close to the market price? The narrative leans heavily on pipeline depth, earnings power, and how margins could reset over time.

Result: Fair Value of $112.55 (OVERVALUED)

However, this balance could shift if Keytruda faces faster than expected erosion around its 2028 patent cliff or if regulatory setbacks hit key pipeline assets.

Another view: market pricing versus our DCF

While the popular narrative suggests Merck is around 1% overvalued at $113.45 versus a $112.55 fair value, the SWS DCF model points a very different way. It values future cash flows at $228.62 per share, which would indicate the stock trades at a steep discount. Which perspective aligns with the level of risk you are willing to take?

Next Steps

With such mixed signals around valuation and future prospects, this is a good moment to move fast, review the underlying data yourself, and weigh both the 2 key rewards and 4 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you risk missing other opportunities that better fit your goals, preferred risk level, or income needs.

• Zero in on financial strength by scanning companies on the solid balance sheet and fundamentals stocks screener (45 results).
• Spot potential value opportunities before the crowd by checking out the 47 high quality undervalued stocks.
• Build a focused watchlist of resilient businesses using the 68 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.